Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jul;5(5):506-15.
doi: 10.1186/1479-7364-5-5-506.

e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure

Houda Hachad  1 , Casey Lynnette Overby, Sophie Argon, Catherine K Yeung, Isabelle Ragueneau-Majlessi, René H Levy
Affiliations
Review

e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure

Houda Hachad et al. Hum Genomics. 2011 Jul.

Abstract

e-PKGene (www.pharmacogeneticsinfo.org) is a manually curated knowledge product developed in the Department of Pharmaceutics at the University of Washington, USA. The tool integrates information from the literature, public repositories, reference textbooks, product prescribing labels and clinical review sections of new drug approval packages. The database's easy-to-use web portal offers tools for visualisation, reporting and filtering of information. The database helps scientists to mine pharmacokinetic and pharmacodynamic information for drug-metabolising enzymes and transporters, and provides access to available quantitative information on drug exposure contained in the literature. It allows in-depth analysis of the impact of genetic variants of enzymes and transporters on pharmacokinetic responses to drugs and metabolites. This review gives a brief description of the database organisation, its search functionalities and examples of use.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Example of a summary of genetic information for the CYP2D6 polymorphic enzyme (partial view). Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 2
Figure 2
Example of initial search page. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 3
Figure 3
Sample search results screen, with gene of interest (CYP2D6) highlighted. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 4
Figure 4
Sample 'impact of variants' screen (partial view), with highlighted citation of interest. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 5
Figure 5
Sample 'citation display window' for PMID 17947222. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 6
Figure 6
Sample 'impact of pharmacokinetics' screen for PMID 17947222. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 7
Figure 7
Sample 'full study set' screen for PMID 17947222. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 8
Figure 8
Examples of searches by (A) gene or (B) population. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
Figure 9
Figure 9
Example of drug summary from e-PKGene pilot version. Display from e-PKGene ((http://www.pharmacogeneticsinfo.org); accessed 18th November 2010).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lesko LJ, Woodcock J. 'Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective'. Nat Rev Drug Discov. 2004;3:763–769. doi: 10.1038/nrd1499. - DOI - PubMed
    1. Katz DA, Murray B, Bhathena A, Sahelijo L. 'Defining drug disposition determinants: A pharmacogenetic-pharmacokinetic strategy'. Nat Rev Drug Discov. 2008;7:293–305. doi: 10.1038/nrd2486. - DOI - PubMed
    1. Wilkinson GR. 'Drug metabolism and variability among patients in drug response'. N Engl J Med. 2005;352:2211–2221. doi: 10.1056/NEJMra032424. - DOI - PubMed
    1. Aoki M, Terada T, Ogasawara K, Katsura T. et al.Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenet Genomics. 2009;19:647–656. doi: 10.1097/FPC.0b013e32832fabd3. - DOI - PubMed
    1. Woodcock J, Lesko LJ. 'Pharmacogenetics -- Tailoring treatment for the outliers'. N Engl J Med. 2009;360:811–813. doi: 10.1056/NEJMe0810630. - DOI - PubMed

Substances